Journal article
Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease
Abstract
BACKGROUND: The RE-LY trial (Randomized Evaluation of Long-Term Anticoagulant Therapy) compared dabigatran 150 and 110 mg twice daily with warfarin in 18 113 patients with atrial fibrillation. Those with prosthetic heart valves, significant mitral stenosis, and valvular heart disease (VHD) requiring intervention were excluded. Others with VHD were included.
METHODS: This is a post hoc analysis of the RE-LY trial.
Authors
Ezekowitz MD; Nagarakanti R; Noack H; Brueckmann M; Litherland C; Jacobs M; Clemens A; Reilly PA; Connolly SJ; Yusuf S
Journal
Circulation, Vol. 134, No. 8, pp. 589–598
Publisher
Wolters Kluwer
Publication Date
August 23, 2016
DOI
10.1161/circulationaha.115.020950
ISSN
0009-7322